Valneva to Engage with Investors at June Conferences

Valneva ( (VALN) ) has shared an announcement.

On May 26, 2025, Valneva SE announced its participation in upcoming investor conferences in the United States and Europe in June 2025. The company’s senior management will discuss Valneva’s commercial stage vaccines and its differentiated portfolio, including VLA15, the leading Lyme disease vaccine candidate in a Phase 3 trial. This participation is expected to enhance Valneva’s visibility and engagement with institutional investors, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (VALN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s overall stock score is driven primarily by its financial performance challenges, including consistent losses and negative cash flow. Technical analysis indicates bearish sentiment, and the company’s valuation reflects its financial difficulties. The earnings call highlighted strong revenue growth and regulatory progress, which are positive but insufficient to offset the financial and operational challenges. Investors should be cautious, considering the company’s reliance on future approvals and commercialization for sustained profitability.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, focusing on unmet medical needs. The company applies its expertise across multiple vaccine modalities to provide first-, best-, or only-in-class vaccine solutions. Valneva has a strong track record of advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines. Its pipeline includes a Lyme disease vaccine candidate partnered with Pfizer, a Shigella vaccine candidate, and other vaccines against global public health threats.

Average Trading Volume: 81,068

Technical Sentiment Signal: Sell

Current Market Cap: $529.5M

Find detailed analytics on VALN stock on TipRanks’ Stock Analysis page.